Study of ORKA-002 for moderate-to-severe plaque psoriasis
Part of Skin clinical trials.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You must have been diagnosed with plaque psoriasis for more than 6 months.
- Your psoriasis must be moderate to severe, covering at least 10% of your body.
- You must be a candidate for systemic therapy (pills or injections) or light therapy.
- You cannot have other forms of psoriasis, such as guttate or pustular psoriasis.
- You must not have a history of certain cancers (except for non-melanoma skin cancer or cancer fully cured more than 5 years ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a continuation for people who already took ORKA-001 for plaque psoriasis and did well. It tests whether staying on the medicine keeps helping without any new safety concerns.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This study tests a new oral pill (HSK47388) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing the severity and area of psoriasis over 12 weeks.
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.